|
1
|
ARID1A mutations in endometriosis-associated ovarian carcinomas.
|
N Engl J Med
|
2010
|
13.07
|
|
2
|
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
|
Lancet Oncol
|
2012
|
5.70
|
|
3
|
Mutation of FOXL2 in granulosa-cell tumors of the ovary.
|
N Engl J Med
|
2009
|
5.63
|
|
4
|
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
|
Nature
|
2011
|
3.22
|
|
5
|
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
|
BMC Cancer
|
2007
|
3.09
|
|
6
|
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.
|
Clin Cancer Res
|
2007
|
2.94
|
|
7
|
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
|
J Pathol
|
2011
|
2.64
|
|
8
|
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
|
Genome Biol
|
2010
|
2.60
|
|
9
|
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.
|
J Clin Pathol
|
2007
|
2.48
|
|
10
|
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
|
Lancet Oncol
|
2013
|
2.48
|
|
11
|
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.
|
Mod Pathol
|
2007
|
2.47
|
|
12
|
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.
|
BMC Cancer
|
2008
|
2.47
|
|
13
|
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
|
J Pathol
|
2013
|
2.35
|
|
14
|
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.
|
N Engl J Med
|
2011
|
2.25
|
|
15
|
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
|
Clin Cancer Res
|
2007
|
2.22
|
|
16
|
CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer.
|
Ann Surg
|
2007
|
2.10
|
|
17
|
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.
|
Cancer Res
|
2009
|
2.01
|
|
18
|
Amplification of 11q13 in ovarian carcinoma.
|
Genes Chromosomes Cancer
|
2008
|
2.01
|
|
19
|
Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
|
J Pathol
|
2011
|
1.91
|
|
20
|
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
|
Mod Pathol
|
2008
|
1.90
|
|
21
|
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression.
|
Cancer Res
|
2004
|
1.90
|
|
22
|
Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
|
Int J Gynecol Pathol
|
2010
|
1.87
|
|
23
|
Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
|
Obstet Gynecol
|
2012
|
1.86
|
|
24
|
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement.
|
Am J Surg Pathol
|
2012
|
1.83
|
|
25
|
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
|
Clin Cancer Res
|
2011
|
1.79
|
|
26
|
Type I gamma phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with mu 1B adaptin.
|
J Cell Biol
|
2007
|
1.78
|
|
27
|
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases.
|
Breast Cancer Res Treat
|
2007
|
1.75
|
|
28
|
Type-specific cell line models for type-specific ovarian cancer research.
|
PLoS One
|
2013
|
1.73
|
|
29
|
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer.
|
J Pathol
|
2012
|
1.72
|
|
30
|
Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray.
|
Am J Clin Pathol
|
2002
|
1.67
|
|
31
|
Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.
|
Clin Cancer Res
|
2004
|
1.67
|
|
32
|
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening.
|
J Pathol
|
2004
|
1.59
|
|
33
|
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.
|
PLoS One
|
2011
|
1.57
|
|
34
|
Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.
|
Gynecol Oncol
|
2011
|
1.55
|
|
35
|
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.
|
BMC Cancer
|
2008
|
1.54
|
|
36
|
Identification of sister chromatids by DNA template strand sequences.
|
Nature
|
2009
|
1.53
|
|
37
|
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma.
|
Proc Natl Acad Sci U S A
|
2012
|
1.51
|
|
38
|
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
|
Cancer
|
2005
|
1.47
|
|
39
|
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
|
J Pathol
|
2013
|
1.47
|
|
40
|
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management.
|
Clin Cancer Res
|
2005
|
1.46
|
|
41
|
Hereditary diffuse gastric cancer: association with lobular breast cancer.
|
Fam Cancer
|
2008
|
1.45
|
|
42
|
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
|
BMC Cancer
|
2009
|
1.43
|
|
43
|
ESR1 gene amplification in breast cancer: a common phenomenon?
|
Nat Genet
|
2008
|
1.33
|
|
44
|
Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.
|
Gynecol Oncol
|
2005
|
1.33
|
|
45
|
Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.
|
Breast Cancer Res Treat
|
2007
|
1.30
|
|
46
|
Evolutionary concepts in biobanking - the BC BioLibrary.
|
J Transl Med
|
2009
|
1.29
|
|
47
|
Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study.
|
Am J Surg Pathol
|
2010
|
1.29
|
|
48
|
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.
|
J Pathol
|
2010
|
1.28
|
|
49
|
A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma.
|
Genes Chromosomes Cancer
|
2004
|
1.24
|
|
50
|
The role of the fallopian tube in ovarian cancer.
|
Clin Adv Hematol Oncol
|
2012
|
1.23
|
|
51
|
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
1.22
|
|
52
|
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival.
|
BMC Cancer
|
2010
|
1.22
|
|
53
|
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer.
|
Genome Biol
|
2012
|
1.21
|
|
54
|
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
|
Gynecol Oncol
|
2008
|
1.20
|
|
55
|
Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.
|
Mod Pathol
|
2006
|
1.19
|
|
56
|
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
|
Neoplasia
|
2008
|
1.19
|
|
57
|
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
|
PLoS One
|
2011
|
1.18
|
|
58
|
NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis.
|
Oncogene
|
2005
|
1.16
|
|
59
|
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer.
|
Mol Oncol
|
2008
|
1.16
|
|
60
|
Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma.
|
BMC Med
|
2007
|
1.15
|
|
61
|
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
|
Clin Cancer Res
|
2010
|
1.14
|
|
62
|
Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer.
|
Breast Cancer Res
|
2010
|
1.14
|
|
63
|
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
|
Cancer Res
|
2004
|
1.13
|
|
64
|
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
|
Mod Pathol
|
2012
|
1.12
|
|
65
|
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study.
|
Breast Cancer Res
|
2008
|
1.11
|
|
66
|
Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
|
Gynecol Oncol
|
2009
|
1.10
|
|
67
|
De novo expression of CD44 variants in sporadic and hereditary gastric cancer.
|
Lab Invest
|
2010
|
1.10
|
|
68
|
Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
|
Int J Gynecol Pathol
|
2005
|
1.10
|
|
69
|
Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe.
|
Diagn Mol Pathol
|
2005
|
1.09
|
|
70
|
The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.
|
PLoS One
|
2009
|
1.07
|
|
71
|
Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy.
|
Cancer
|
2008
|
1.06
|
|
72
|
Calculator for ovarian carcinoma subtype prediction.
|
Mod Pathol
|
2010
|
1.04
|
|
73
|
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
|
BMC Cancer
|
2014
|
1.03
|
|
74
|
Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer.
|
Breast Cancer Res Treat
|
2006
|
1.02
|
|
75
|
FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary.
|
Am J Surg Pathol
|
2011
|
1.01
|
|
76
|
Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.
|
Am J Surg Pathol
|
2008
|
1.00
|
|
77
|
Adult-type granulosa cell tumors and FOXL2 mutation.
|
Cancer Res
|
2009
|
1.00
|
|
78
|
Hereditary diffuse gastric cancer: prophylactic surgical oncology implications.
|
Surg Clin North Am
|
2008
|
1.00
|
|
79
|
Frequency of known gene rearrangements in endometrial stromal tumors.
|
Am J Surg Pathol
|
2011
|
0.98
|
|
80
|
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
|
Mod Pathol
|
2006
|
0.97
|
|
81
|
Does massively parallel DNA resequencing signify the end of histopathology as we know it?
|
J Pathol
|
2010
|
0.95
|
|
82
|
HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.
|
Ann Surg
|
2010
|
0.94
|
|
83
|
The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
|
Gynecol Oncol
|
2007
|
0.94
|
|
84
|
Using next-generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities.
|
J Pathol
|
2011
|
0.94
|
|
85
|
Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy.
|
Obstet Gynecol
|
2015
|
0.93
|
|
86
|
Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.
|
Orphanet J Rare Dis
|
2013
|
0.93
|
|
87
|
Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
|
Mol Cell Biol
|
2007
|
0.93
|
|
88
|
Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
|
Am J Surg Pathol
|
2015
|
0.91
|
|
89
|
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
|
Breast Cancer Res Treat
|
2009
|
0.91
|
|
90
|
Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites.
|
Int J Gynecol Pathol
|
2011
|
0.91
|
|
91
|
The tubal hypothesis of ovarian cancer: caution needed.
|
Lancet Oncol
|
2011
|
0.90
|
|
92
|
FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines.
|
Mod Pathol
|
2013
|
0.90
|
|
93
|
P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.
|
Mod Pathol
|
2010
|
0.89
|
|
94
|
Targeted mutation analysis of endometrial clear cell carcinoma.
|
Histopathology
|
2015
|
0.89
|
|
95
|
beta-catenin (CTNNB1) gene amplification: a new mechanism of protein overexpression in cancer.
|
Genes Chromosomes Cancer
|
2005
|
0.89
|
|
96
|
Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
|
Histopathology
|
2013
|
0.88
|
|
97
|
Familial rhabdoid tumour 'avant la lettre'--from pathology review to exome sequencing and back again.
|
J Pathol
|
2013
|
0.88
|
|
98
|
Periodic acid-schiff is superior to hematoxylin and eosin for screening prophylactic gastrectomies from CDH1 mutation carriers.
|
Am J Surg Pathol
|
2010
|
0.86
|
|
99
|
Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
|
Am J Surg Pathol
|
2013
|
0.85
|
|
100
|
Ovarian cellular fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction from diffuse adult granulosa cell tumor.
|
Am J Surg Pathol
|
2013
|
0.85
|
|
101
|
Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes.
|
Breast Cancer Res Treat
|
2010
|
0.84
|
|
102
|
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.
|
Cancers (Basel)
|
2010
|
0.83
|
|
103
|
The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent.
|
BMC Genomics
|
2011
|
0.82
|
|
104
|
Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement.
|
Am J Surg Pathol
|
2013
|
0.81
|
|
105
|
Pregnancy after prophylactic total gastrectomy.
|
Fam Cancer
|
2010
|
0.81
|
|
106
|
Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.
|
Biopreserv Biobank
|
2013
|
0.81
|
|
107
|
Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors.
|
Mod Pathol
|
2012
|
0.81
|
|
108
|
Cancer genomics: why rare is valuable.
|
J Mol Med (Berl)
|
2015
|
0.80
|
|
109
|
Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.
|
Histopathology
|
2013
|
0.80
|
|
110
|
Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer.
|
Anticancer Res
|
2008
|
0.79
|
|
111
|
Mutation discovery in regions of segmental cancer genome amplifications with CoNAn-SNV: a mixture model for next generation sequencing of tumors.
|
PLoS One
|
2012
|
0.79
|
|
112
|
Dicer and Drosha in ovarian cancer.
|
N Engl J Med
|
2009
|
0.79
|
|
113
|
YWHAE-FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumor.
|
Hum Pathol
|
2012
|
0.78
|
|
114
|
Screening of symptomatic women for ovarian cancer.
|
Lancet Oncol
|
2012
|
0.78
|
|
115
|
Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
|
Clin Cancer Res
|
2011
|
0.77
|
|
116
|
Surgical staging of early stage epithelial ovarian cancer.
|
Gynecol Oncol
|
2011
|
0.77
|
|
117
|
Boveri at 100: Theodor Boveri and genetic predisposition to cancer.
|
J Pathol
|
2014
|
0.77
|
|
118
|
Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
|
Am J Surg Pathol
|
2017
|
0.77
|
|
119
|
Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma.
|
Int J Gynecol Cancer
|
2015
|
0.76
|
|
120
|
Correction: Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research.
|
PLoS One
|
2013
|
0.76
|
|
121
|
FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors.
|
Am J Surg Pathol
|
2015
|
0.75
|
|
122
|
Diagnostic uncertainty in the interpretation of small atypical acinar lesions of prostate.
|
Am J Surg Pathol
|
2010
|
0.75
|
|
123
|
Molecular determination of the breakpoints of a 161 556 bp deletion at chromosome 13q34 that presented as severe factor VII deficiency in a neonate.
|
Br J Haematol
|
2007
|
0.75
|
|
124
|
Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status.
|
Histopathology
|
2013
|
0.75
|
|
125
|
BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.
|
Int J Gynecol Cancer
|
2016
|
0.75
|